Erratum: Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota (Scientific Reports (2017) 7 (41802) DOI: 10.1038/srep41802);Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Harach, T ^a   Marungruang, N ^b   Duthilleul, N ^a   Cheatham, V ^a   Mc Coy, K D ^c   Frisoni, G ^d   Neher, J J ^e,f   Fak F ^b   Jucker, M ^e,f   Lasser, T ^a   Bolmont, T ^a,g  

^a EPFL   (Switzerland)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g Stemedica International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011954434     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46856     Document Type: Erratum

References (45)

1. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356, doi: 10.1126/science.1072994 (2002).
2. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121-141, doi: 10.1016/j.cell.2014.03.011 (2014).
3. Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336, 1268-1273, doi: 10.1126/science.1223490 (2012).
4. O'Toole, P. W. & Jeffery, I. B. Gut microbiota and aging. Science 350, 1214-1215, doi: 10.1126/science.aac8469 (2015).
5. Scheperjans, F. et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord, doi: 10.1002/mds.26069 (2014).
6. Collins, S. M. & Bercik, P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003-2014, doi: 10.1053/j.gastro.2009.01.075 (2009).
7. Cryan, J. F. & O'Mahony, S. M. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society 23, 187-192, doi: 10.1111/j.1365-2982.2010.01664.x (2011).
8. Dinan, T. G. & Cryan, J. F. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology 37, 1369-1378, doi: 10.1016/j.psyneuen.2012.03.007 (2012).
9. Forsythe, P., Sudo, N., Dinan, T., Taylor, V. H. & Bienenstock, J. Mood and gut feelings. Brain, behavior, and immunity 24, 9-16, doi: 10.1016/j.bbi.2009.05.058 (2010).
10. Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451-1463, doi: 10.1016/j.cell.2013.11.024 (2013).
11. Berer, K. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538-541, doi: 10.1038/nature10554 (2011).
12. Cattaneo, A. et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiology of aging 49, 60-68, doi: 10.1016/j.neurobiolaging.2016.08.019 (2016).
13. Minter, M. R. et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Scientific reports 6, 30028, doi: 10.1038/srep30028 (2016).
14. Radde, R. et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7, 940-946, doi: 10.1038/sj.embor.7400784 (2006).
15. Rabot, S. et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 4948-4959, doi: 10.1096/fj.10-164921 (2010).
16. Fernandez-Gamba, A., Leal, M. C., Morelli, L. & Castano, E. M. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. Current pharmaceutical design 15, 3644-3655 (2009).
17. Miners, J. S., Barua, N., Kehoe, P. G., Gill, S. & Love, S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. Journal of neuropathology and experimental neurology 70, 944-959, doi: 10.1097/NEN.0b013e3182345e46 (2011).
18. Bhattacharjee, S. & Lukiw, W. J. Alzheimer's disease and the microbiome. Front Cell Neurosci 7, 153, doi: 10.3389/fncel.2013.00153 (2013).
19. Collins, S. M., Surette, M. & Bercik, P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 10, 735-742, doi: 10.1038/nrmicro2876 (2012).
20. Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262-1267, doi: 10.1126/science.1223813 (2012).
21. Ericsson, A. C. et al. Effects of vendor and genetic background on the composition of the fecal microbiota of inbred mice. PloS one 10, e0116704, doi: 10.1371/journal.pone.0116704 (2015).
22. Reardon, S. A mouse's house may ruin experiments. Nature 530, 264, doi: 10.1038/nature.2016.19335 (2016).
23. Couturier-Maillard, A. et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. The Journal of clinical investigation 123, 700-711, doi: 10.1172/JCI62236 (2013).
24. Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 110, 9066-9071, doi: 10.1073/pnas.1219451110 (2013).
25. Haan, M. N. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nature clinical practice. Neurology 2, 159-166, doi: 10.1038/ncpneuro0124 (2006).
26. Ishibashi, K., Onishi, A., Fujiwara, Y., Ishiwata, K. & Ishii, K. Plasma Glucose Levels Affect Cerebral 18F-FDG Distribution in Cognitively Normal Subjects With Diabetes. Clinical nuclear medicine, doi: 10.1097/RLU.0000000000001147 (2016).
27. Pimplikar, S. W. Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. Journal of clinical immunology 34 Suppl 1, S64-69, doi: 10.1007/s10875-014-0032-5 (2014).
28. Tang, Y. et al. Early inflammation-associated factors blunt sterol regulatory element-binding proteins-1-mediated lipogenesis in high-fat diet-fed APP/PSEN1dE9 mouse model of Alzheimer's disease. Journal of neurochemistry, doi: 10.1111/jnc.13437 (2015).
29. Kumar, D. K. et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Science translational medicine 8, 340ra372, doi: 10.1126/scitranslmed.aaf1059 (2016).
30. Dolpady, J. et al. Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2, 3-Dioxygenase-Enriched Tolerogenic Intestinal Environment. Journal of diabetes research 2016, 7569431, doi: 10.1155/2016/7569431 (2016).
31. Lavasani, S. et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PloS one 5, e9009, doi: 10.1371/journal.pone.0009009 (2010).
32. Schippa, S. et al. A distinctive 'microbial signature' in celiac pediatric patients. BMC microbiology 10, 175, doi: 10.1186/1471-2180- 10-175 (2010).
33. Shen, X. J. et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut microbes 1, 138-147, doi: 10.4161/gmic.1.3.12360 (2010).
34. Matziouridou, C., Marungruang, N., Nguyen, T. D., Nyman, M. & Fak, F. Lingonberries reduce atherosclerosis in Apoe-/- mice in association with altered gut microbiota composition and improved lipid profile. Molecular nutrition & food research, doi: 10.1002/ mnfr.201500738 (2016).
35. Anand, R., Gill, K. D. & Mahdi, A. A. Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology 76 Pt A, 27-50, doi: 10.1016/j.neuropharm.2013.07.004 (2014).
36. Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18, 965-977, doi: 10.1038/nn.4030 (2015).
37. Heneka, M. T. et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678, doi: 10.1038/nature11729 (2013).
38. Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 228-231, doi: 10.1126/science.1179721 (2010).
39. Klindworth, A. et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencingbased diversity studies. Nucleic Acids Res 41, e1, doi: 10.1093/nar/gks808 (2013).
40. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7, 335-336, doi: 10.1038/ nmeth.f.303 (2010).
41. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460-2461, doi: 10.1093/ bioinformatics/btq461 (2010).
42. DeSantis, T. Z. et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 72, 5069-5072, doi: 10.1128/AEM.03006-05 (2006).
43. Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73, 5261-5267, doi: 10.1128/AEM.00062-07 (2007).
44. Klipper-Aurbach, Y. et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Medical hypotheses 45, 486-490 (1995).
45. Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol 12, R60, doi: 10.1186/gb-2011-12-6-r60 (2011).